Global Respiratory Drugs Market to 2022 - Pipeline and Market Characterized by Growing Prominence of Targeted Therapies, With Asthma and Cystic Fibrosis Leading the Way - Research and Markets
Theravance THRX reported second-quarter earnings that matched our expectations, and we are keeping our fair value estimate at $29 per share. The company continues to make progress in each of its programs, namely the addition of a second Phase IIb compound in the Beyond Advair trials and completion ...
Global Fibromyalgia Pipeline Report 2016 - Review of 7 Companies & Drug Profiles - Research and Markets
Biotech companies' returns have diverged from the broader market in recent weeks amid concerns over greater regulation and price discounting.